Publications by authors named "P Weeke"
Background: Heart failure with mildly reduced or preserved ejection fraction (hereafter referred to as HFpEF) is the most common type of heart failure and is associated with a high risk of hospitalisation and death, especially in patients with overweight, obesity, or type 2 diabetes. In the STEP-HFpEF and STEP-HFpEF DM trials, semaglutide improved heart failure-related symptoms and physical limitations in participants with HFpEF. Whether semaglutide also reduces clinical heart failure events in this group remains to be established.
View Article and Find Full Text PDFBackground: Patients with overweight and obesity are at increased risk of death from multiple causes, including cardiovascular (CV) death, with few therapies proven to reduce the risk.
Objectives: This study sought to assess the effect of semaglutide 2.4 mg on all-cause death, CV death, and non-CV death, including subcategories of death and death from coronavirus disease-2019 (COVID-19).
Article Synopsis
- Semaglutide, a GLP-1 receptor agonist used for weight loss, may lower the risk of serious cardiovascular issues in individuals with obesity, but its specific effects on those with pre-existing heart conditions, like atherosclerotic cardiovascular disease and heart failure, were unclear.
- The SELECT trial, a comprehensive study involving adult participants with cardiovascular disease and high BMI, examined the impact of weekly injections of semaglutide versus placebo on heart-related outcomes, particularly focusing on those with varying types of heart failure.
- Researchers looked for differences in cardiovascular events, analyzing data to see if treatment efficacy and safety were affected by heart failure type and participants’ initial health characteristics.
Objective: To evaluate the cardiovascular effects of semaglutide by baseline glycated hemoglobin (HbA1c) and change in HbA1c in a prespecified analysis of Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT).
Research Design And Methods: In SELECT, people with overweight or obesity and atherosclerotic cardiovascular disease without diabetes were randomized to weekly semaglutide 2.4 mg or placebo.